In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Ceribell, Inc. (CBLL – Research Report), with a price target of $36.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Josh Jennings has given his Buy rating due to a combination of factors including Ceribell, Inc.’s consistent ability to exceed quarterly sales expectations and its robust financial performance. The company reported a significant 42% increase in total revenue for the first quarter compared to the previous year, surpassing market forecasts. This marks the third consecutive quarter where Ceribell has outperformed since going public, indicating strong commercial traction and expansion into new and existing accounts.
Additionally, Ceribell has raised its full-year revenue guidance, now anticipating a growth range of 27% to 33%, which is higher than previous estimates and market expectations. Despite potential tariff challenges, the company maintains impressive gross margins in the high-70s to low-80s range, showcasing its resilience and operational efficiency. These positive financial indicators, alongside a substantial cash reserve, underpin Jennings’s confidence in the company’s continued growth and justify the Buy rating.
Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Establishment Labs Holdings, and Edwards Lifesciences. According to TipRanks, Jennings has an average return of 2.2% and a 50.10% success rate on recommended stocks.